Etoricoxib dose to be increased from 50 mg daily to 60 mg/day.
Other studies have also found adverse pregnancy outcomes or birth defects associated with the use of Dendrogel and an implant or infusion of Vincristine (Vincristel®). These outcomes have generally involved small or very early pregnancies, however, the safety of use Dendrogel remains unproven.[3,4,5,6,7]
Some patients in controlled clinical trials experienced adverse birth outcomes or symptoms, and the possible significance of this has not been fully elucidated. More research is necessary to determine if birth outcomes and symptoms are related to the administration of Dendrogel or Vincristine and whether not these symptoms are transient.
In pat